1
|
Henning C, Wang J, Swift R, Eades B, Spektor TM, Berenson JR. Removal of a Silicone Gel Breast Implant in a Multiple Myeloma Patient Improved Disease Status: A Case Report. Case Rep Oncol 2020; 13:1103-1108. [PMID: 33082755 PMCID: PMC7548844 DOI: 10.1159/000508494] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 05/06/2020] [Indexed: 11/19/2022] Open
Abstract
A 52-year-old African-American woman with a prior history of monoclonal gammopathy of undetermined significance (MGUS) developed infiltrating ductal carcinoma of the left breast. Following a mastectomy, she underwent reconstruction with a silicone gel breast implant. Three years later, her MGUS had progressed to active multiple myeloma (MM). She had a minimal response after two different regimens of bortezomib-based treatments and monthly zoledronic acid, and was placed on maintenance therapy with bortezomib, intravenous dexamethasone, and oral methylprednisolone, as well as ongoing monthly zoledronic acid. After 1 year of this maintenance therapy, during which her myeloma markers remained unchanged, she had her silicone implant replaced with saline. Despite no change in her myeloma treatment, her laboratory values began to steadily improve following removal of the silicone implant. Her M-protein decreased from 2.14 to 0.83 g/dL and her IgG levels from 3,330 to 1,210 mg/dL following replacement of her silicone implant with saline. To our knowledge, this is the first report in which removal of silicone implants improved the clinical status of a patient with MM following a year of maintenance therapy during which the patient's myeloma laboratory values remained unchanged. Further studies are warranted to determine if silicone breast implant removal can, in fact, improve MM patients' disease status.
Collapse
Affiliation(s)
- Chace Henning
- Institute for Myeloma & Bone Cancer Research, West Hollywood, California, USA
| | - James Wang
- Institute for Myeloma & Bone Cancer Research, West Hollywood, California, USA
| | - Regina Swift
- Institute for Myeloma & Bone Cancer Research, West Hollywood, California, USA
| | - Benjamin Eades
- Institute for Myeloma & Bone Cancer Research, West Hollywood, California, USA
| | | | - James R Berenson
- Institute for Myeloma & Bone Cancer Research, West Hollywood, California, USA.,Oncotherapeutics, West Hollywood, California, USA
| |
Collapse
|
2
|
Rupani A, Frame JD, Kamel D. Lymphomas Associated with Breast Implants: A Review of the Literature. Aesthet Surg J 2015; 35:533-44. [PMID: 26116741 DOI: 10.1093/asj/sjv016] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Recently there have been concerns raised about anaplastic large cell lymphoma (ALCL) associated with breast implants. OBJECTIVES The main aim of this article was to review and analyze the published literature specifically for hematopoietic malignancies associated with breast implants and postulate a hypothesis for their etiology and pathogenesis. METHODS The PubMed database was searched using key words "lymphoma" and "breast implants" for published papers and abstracts on implant-associated hematopoietic malignancies. RESULTS The authors found 83 published cases reported of lymphomas associated with breast implants in the medical literature. The reported cases involved various subtypes of lymphomas and the majority were ALCL, of which 66 were confirmed as ALK negative; however there was no association with any particular type of implant. The more aggressive cases and reported low death rate appeared to be related to the presence of breast masses at the time of presentation rather than effusion. The remaining reports were occasional case reports of T-cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, primary effusion lymphoma and lymphoplasmacytic lymphoma. CONCLUSIONS Considering the many thousands of women that have breast implants every year; the compiled data show that there is a very small risk of developing lymphoma. Increased awareness of association between implants and ALCL is needed globally and prospective patients considering breast implants should be fully informed of the risk. As the behavior of ALCL in these cases was indolent as compared with other primary breast lymphomas, it could suggest an abnormal reactive process. LEVEL OF EVIDENCE 3
Collapse
Affiliation(s)
- Asha Rupani
- Dr Rupani is a Specialist Registrar and Dr Kamel is a Consultant Histopathologist, Department of Histopathology, Broomfield Hospital, Chelmsford, United Kingdom. Dr Frame is a Professor of Aesthetic Plastic Surgery at the Post Graduate Medical Institute, Anglia Ruskin University (Chelmsford and Cambridge), Chelmsford, United Kingdom
| | - James D Frame
- Dr Rupani is a Specialist Registrar and Dr Kamel is a Consultant Histopathologist, Department of Histopathology, Broomfield Hospital, Chelmsford, United Kingdom. Dr Frame is a Professor of Aesthetic Plastic Surgery at the Post Graduate Medical Institute, Anglia Ruskin University (Chelmsford and Cambridge), Chelmsford, United Kingdom
| | - Dia Kamel
- Dr Rupani is a Specialist Registrar and Dr Kamel is a Consultant Histopathologist, Department of Histopathology, Broomfield Hospital, Chelmsford, United Kingdom. Dr Frame is a Professor of Aesthetic Plastic Surgery at the Post Graduate Medical Institute, Anglia Ruskin University (Chelmsford and Cambridge), Chelmsford, United Kingdom
| |
Collapse
|
3
|
Csako G, Costello R, Shamim EA, O'Hanlon TP, Tran A, Clauw DJ, Williams HJ, Miller FW. Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study. Arthritis Res Ther 2008; 9:R95. [PMID: 17875216 PMCID: PMC2212583 DOI: 10.1186/ar2295] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2007] [Revised: 08/09/2007] [Accepted: 09/17/2007] [Indexed: 11/14/2022] Open
Abstract
Prior studies have suggested abnormalities of serum proteins, including paraproteins, in women with silicone implants but did not control for the presence of connective-tissue disease (CTD). This retrospective case–control study, performed in tertiary-care academic centers, assessed possible alterations of serum proteins, including paraproteins, in such a population. Seventy-four women with silicone implants who subsequently developed CTD, and 74 age-matched and CTD-matched women without silicone implants, were assessed in the primary study; other groups were used for additional comparisons. Routine serum protein determinations and high-sensitivity protein electrophoresis and immunofixation electrophoresis were performed for detection of paraproteins. Women with silicone implants, either with or without CTD, had significantly lower serum total protein and α1-globulin, α2-globulin, β-globulin, γ-globulin, and IgG levels compared with those without silicone implants. There was no significant difference, however, in the frequency of paraproteinemia between women with silicone implants and CTD (9.5%) and age-matched and CTD-matched women without silicone implants (5.4%) (odds ratio, 1.82; 95% confidence interval, 0.51–6.45). Paraprotein isotypes were similar in the two groups, and the clinical characteristics of the 13 women with paraproteinemia were comparable with an independent population of 10 women with silicone breast implants, CTD, and previously diagnosed monoclonal gammopathies. In summary, this first comprehensive study of serum proteins in women with silicone implants and CTD found no substantially increased risk of monoclonal gammopathy. Women with silicone implants, however, had unexpectedly low serum globulin and immunoglobulin levels, with or without the subsequent development of CTD. The causes and clinical implications of these findings require further investigation.
Collapse
Affiliation(s)
- Gyorgy Csako
- Department of Laboratory Medicine, Clinical Center, NIH, DHHS, 9000 Rockville Pike, Bethesda, MD 20892, USA
| | - Rene Costello
- Department of Laboratory Medicine, Clinical Center, NIH, DHHS, 9000 Rockville Pike, Bethesda, MD 20892, USA
| | - Ejaz A Shamim
- Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, DHHS, 9000 Rockville Pike, Bethesda, MD 20892, USA
| | - Terrance P O'Hanlon
- Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, DHHS, 9000 Rockville Pike, Bethesda, MD 20892, USA
| | - Anthony Tran
- Department of Laboratory Medicine, Clinical Center, NIH, DHHS, 9000 Rockville Pike, Bethesda, MD 20892, USA
- Association of Public Health Laboratories, 8515 Georgia Avenue, Suite 700, Silver Spring, MD 20910, USA
| | - Daniel J Clauw
- Division of Rheumatology, Department of Medicine, University of Michigan Medical School, 101 Simpson Drive, Ann Arbor, MI 48109, USA
| | - H James Williams
- Division of Rheumatology, Department of Internal Medicine, University of Utah Medical Center, 50 North Medical Drive, Salt Lake City, UT 84132, USA
| | - Frederick W Miller
- Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, DHHS, 9000 Rockville Pike, Bethesda, MD 20892, USA
| |
Collapse
|
4
|
Brisson J, Holowaty EJ, Villeneuve PJ, Xie L, Ugnat AM, Latulippe L, Mao Y. Cancer incidence in a cohort of Ontario and Quebec women having bilateral breast augmentation. Int J Cancer 2006; 118:2854-62. [PMID: 16381020 DOI: 10.1002/ijc.21711] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The possibility that women, who receive breast implants for cosmetic purposes, have increased long-term risks of developing cancer continues to be debated. The objective of our study was to prospectively examine cancer incidence among women who received breast implants. A cohort was assembled of 24,558 women, 18 years of age and older, who underwent bilateral cosmetic breast augmentation, and 15,893 women who underwent other cosmetic procedures in Ontario or Quebec between 1974 and 1989. These plastic surgery patients were selected from the same clinics as the implant population. Incident cancers were identified by linking to Canadian registry data up to December 31, 1997. In total, 676 cancers were identified among women who received breast implants compared to 899 expected based on general population rates (standardized incidence ratio (SIR) = 0.75; 95% confidence interval (CI) = 0.70-0.81). Overall cancer incidence rates among women who received breast implants were similar to that of the other plastic surgery patients (relative risk (RR) = 0.91, 95% CI = 0.81-1.02). However, women who received breast implants had lower breast cancer rates than the plastic surgery patients (RR = 0.64, 95% CI = 0.53-0.79). No increased risks were observed among the implant population for any of the other cancer sites examined. Comparisons involving only women who received breast implants found no association between long-term breast cancer incidence and implant site (submuscular vs. subglandular), fill (saline vs. silicone) or envelope (polyurethane-coated or not). In conclusion, women undergoing cosmetic breast augmentation do not appear to be at an increased long-term risk of developing cancer.
Collapse
Affiliation(s)
- Jacques Brisson
- Department of Social and Preventive Medicine, Laval University, Laval, QC, Canada
| | | | | | | | | | | | | |
Collapse
|
5
|
Shanklin DR, Smalley DL. The immunopathology of siliconosis. History, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone. Immunol Res 1999; 18:125-73. [PMID: 9951648 DOI: 10.1007/bf02788777] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Recent evidence confirms the fundamental involvement of the human immune system in the reaction to implantation of silicone-based medical devices. An as yet-to-be particularized epitope of many complex substances sharing siloxane structures is presented through the MHC-II apparatus with development and retention of T cell memory. This memory can be tested for in practical terms using one or more forms of silica, which links the immuno-histopathology and autoimmune attributes of "silicosis" with those of "siliconosis." The lesions of siliconosis are typical of those for persistent antigens and delayed, cell mediated hypersensitivity. The basic descriptive pathology of the reaction to silicone has been known since soon after introduction of silicones in medical procedures, with the exception of some details related to the more recent discoveries on the role of cytokines in the immunopathic process. The clinical consequences of siliconosis are common and can be severe in some individuals implanted with silicone devices.
Collapse
Affiliation(s)
- D R Shanklin
- Department of Pathology, University of Tennessee, Memphis 38163, USA
| | | |
Collapse
|
6
|
Abstract
BACKGROUND Although silicone breast implants have been linked to various short-term complications, less is known about their long-range effects. Most attention has focused on connective tissue disorders, but the range of immunologic disturbances observed in women with implants suggests that consideration also be given to other chronic diseases, including cancer. The greatest attention has focused on breast cancer, given clinical reports suggesting an association and observations that mammographic visualization is deterred by implants. Findings from epidemiologic studies, however, actually suggest that breast cancer risk might be reduced among women with implants, although the biologic mechanism remains undefined. In addition, most studies do not suggest that women with breast implants have more advanced breast cancer at diagnosis or a worse prognosis than those without implants. The majority of studies have focused on women who received implants for cosmetic reasons, with little previous investigation of women who received implants for breast reconstruction following cancer surgery. In terms of other cancers, animal as well as clinical data suggest potential risks of sarcomas and hematologic cancers, including multiple myeloma. The risk of these cancers has not yet been adequately addressed by epidemiologic studies, although several ongoing studies should provide insights. It will be important for studies to consider effects of other lifestyle factors as well as to analyze relationships according to duration of implantation, a demonstrated determinant of implant deterioration. In addition, consideration should be given to type of implant, including implants with polyurethane foam covers, which can leak toluene diamine, a demonstrated carcinogen in animals.
Collapse
Affiliation(s)
- L A Brinton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892-7374, USA
| | | |
Collapse
|
7
|
Friis S, McLaughlin JK, Mellemkjaer L, Kjøller KH, Blot WJ, Boice JD, Fraumeni JF, Olsen JH. Breast implants and cancer risk in Denmark. Int J Cancer 1997; 71:956-8. [PMID: 9185696 DOI: 10.1002/(sici)1097-0215(19970611)71:6<956::aid-ijc8>3.0.co;2-x] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Although millions of women worldwide have received breast implants for cosmetic or medical reasons, possible late effects (in particular cancer) have not been well studied. To provide quantitative information on cancer occurrence among women undergoing breast implant surgery, 1,135 women treated for cosmetic reasons in Denmark were evaluated. Patients were identified using the nationwide Hospital Discharge Registry with linkage to the nationwide Danish Cancer Registry to determine subsequent cancer incidence. The average age of the women at implant surgery was 31 years, and the average follow-up was 8.4 years, up to a maximum of 17 years. Overall, 27 cancers developed after implant surgery compared with 24.7 expected based on incidence rates from the general population (standardized incidence ratio [SIR] = 1.1; 95% CI: 0.7-1.6). Eight breast cancers were observed vs. 7.8 expected (SIR = 1.0; 95% CI: 0.4-2.0). No evidence was found to link breast implants with increased cancer risk in the decade after surgery. While the results are encouraging, longer follow-up into later life will be necessary to assess fully any possible adverse effects.
Collapse
Affiliation(s)
- S Friis
- Danish Cancer Society, Division of Cancer Epidemiology, Copenhagen
| | | | | | | | | | | | | | | |
Collapse
|